SCI REP-UK 润色咨询

Scientific Reports

出版年份:2011 年文章数:160514 投稿命中率: 开通期刊会员,数据随心看

出版周期:Irregular 自引率:9.1% 审稿周期: 开通期刊会员,数据随心看

前往期刊查询

期刊讨论

  1. [GetPortalCommentsPageByObjectIdResponse(id=601248, encodeId=ba9260124873, content=请问询问稿件状态发哪个邮箱啊 scientificreports@nature.com 我问的这个邮箱一直没有回复我, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=83, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201102/9c373b6157ec4a72af667f0eaee06cc2/38088b6d8f154d46874faf3a78361584.jpg, createdBy=9c075117529, createdName=1462b19em97暂无昵称, createdTime=Wed Jun 03 11:34:22 CST 2020, time=2020-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2213965, encodeId=94542213965a9, content=审稿速度:6.0 | 投稿命中率:50.0<br>经验分享:2024-7-8:记录最新过程,接近3个月了才送外审,速度真的挺慢了。<br>Submission received<br>Submission status Date<br>Submission received 11 Apr 2024<br>Technical check<br>Submission status Date<br>Submission is under technical check 11 Apr 2024<br>Amendment received 16 Apr 2024<br>Amendment received 17 Apr 2024<br>Submission passed technical check 18 Apr 2024<br>Editorial assignment<br>Submission status Date<br>Ready for editorial assignment 18 Apr 2024<br>With editor<br>Submission status Date <br>Editor assigned 02 Jul 2024<br>Peer review<br>Submission status Date<br>Submission under peer review 08 Jul 2024<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=15, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a4339264059, createdName=wzt9715, createdTime=Mon Jul 08 17:18:18 CST 2024, time=2024-07-08, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2215381, encodeId=711222153815e, content=请问大家有没有刊物其他联系方式啊?Technical check已经20天了,中间发了两次邮件给srep@nature.com询问情况没有回复, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=5, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c1e89286195, createdName=ms9000000825188207, createdTime=Wed Jul 17 11:04:00 CST 2024, time=2024-07-17, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2149028, encodeId=0e1221490283b, content=20天了还在技术审查,怎么办, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=78a86574728, createdName=ms9000001459812965, createdTime=Thu Jul 20 16:52:18 CST 2023, time=2023-07-20, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2123237, encodeId=e628212323e60, content=请问Technical check in progress 这个过程需要多少天?谢谢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=84, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1edb5535080, createdName=英雄77, createdTime=Sun Apr 02 08:36:46 CST 2023, time=2023-04-02, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2214210, encodeId=6d832214210af, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向:临床<br>经验分享:Ready for editorial assignment 这个状态1w了,真难顶<a href='/topic/show?id=508e6e03203' target=_blank style='color:#2F92EE;'>#炎症性肠病患者#</a>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=1, topicName=null, topicId=null, topicList=[TopicDto(id=67032, encryptionId=508e6e03203, topicName=炎症性肠病患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9d4c8320348, createdName=ms3000000691298775, createdTime=Wed Jul 10 10:29:55 CST 2024, time=2024-07-10, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=2211101, encodeId=bb8122111016a, content=审稿速度:3.0 | 投稿命中率:75.0<br>偏重的研究方向:转化医学;综合期刊<br>经验分享:2023年度影响因子为4.3分,未来估计在3.5-4.5之间, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=30, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=侠胆医心, createdTime=Sat Jun 22 05:48:52 CST 2024, time=2024-06-22, status=1, ipAttribution=威斯康星), GetPortalCommentsPageByObjectIdResponse(id=2188542, encodeId=ca19218854206, content=偏重的研究方向:炎症性肠病<br>经验分享:接受了,投稿历程发出来给大伙参考一下。<br>Submission history<br>Publishing and rights<br>Submission status Date<br>Submission is in publishing and rights<br>21 Feb 2024<br>Peer review<br>Submission status Date<br>Submission accepted<br>21 Feb 2024<br>Submission under peer review<br>07 Feb 2024<br>Submission passed technical check<br>07 Feb 2024<br>Amendment received<br>07 Feb 2024<br>Revision received<br>31 Jan 2024<br>Submission under peer review<br>24 Jan 2024<br>Submission passed technical check<br>24 Jan 2024<br>Revision received<br>05 Jan 2024<br>Submission under peer review<br>30 Sep 2023<br>Technical check<br>Submission status Date<br>Submission passed technical check<br>30 Sep 2023<br>Amendment received<br>30 Sep 2023<br>Submission is under technical check<br>29 Sep 2023<br>Submission received<br>Submission status Date<br>Submission received<br>29 Sep 2023, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ef635598785, createdName=超超不吵吵, createdTime=Wed Feb 21 18:24:57 CST 2024, time=2024-02-21, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2212907, encodeId=e4f6221290e0d, content=现在是JCR Q1,中科院二区吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=21, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6a638109651, createdName=清清欢, createdTime=Wed Jul 03 08:33:02 CST 2024, time=2024-07-03, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=2206934, encodeId=464822069349a, content=审稿速度:6.0 | 投稿命中率:50.0<br>偏重的研究方向:免疫;肿瘤<br>经验分享:请问大家,有没有人询问审稿进度之后,给重新指派了个编辑的?<br>Editor assigned<br>On 27 May, 2024<br>Editor invited<br>On 28 Mar, 2024<br>Submission checks complete<br>On 28 Mar, 2024<br>First submitted to Scientific Reports<br>On 15 Mar, 2024, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=34, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8a036530258, createdName=ms7000000411552686, createdTime=Mon May 27 20:49:59 CST 2024, time=2024-05-27, status=1, ipAttribution=甘肃省)]
    2020-06-03 1462b19em97暂无昵称

    请问询问稿件状态发哪个邮箱啊 scientificreports@nature.com 我问的这个邮箱一直没有回复我

    6

    展开6条回复
  2. [GetPortalCommentsPageByObjectIdResponse(id=601248, encodeId=ba9260124873, content=请问询问稿件状态发哪个邮箱啊 scientificreports@nature.com 我问的这个邮箱一直没有回复我, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=83, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201102/9c373b6157ec4a72af667f0eaee06cc2/38088b6d8f154d46874faf3a78361584.jpg, createdBy=9c075117529, createdName=1462b19em97暂无昵称, createdTime=Wed Jun 03 11:34:22 CST 2020, time=2020-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2213965, encodeId=94542213965a9, content=审稿速度:6.0 | 投稿命中率:50.0<br>经验分享:2024-7-8:记录最新过程,接近3个月了才送外审,速度真的挺慢了。<br>Submission received<br>Submission status Date<br>Submission received 11 Apr 2024<br>Technical check<br>Submission status Date<br>Submission is under technical check 11 Apr 2024<br>Amendment received 16 Apr 2024<br>Amendment received 17 Apr 2024<br>Submission passed technical check 18 Apr 2024<br>Editorial assignment<br>Submission status Date<br>Ready for editorial assignment 18 Apr 2024<br>With editor<br>Submission status Date <br>Editor assigned 02 Jul 2024<br>Peer review<br>Submission status Date<br>Submission under peer review 08 Jul 2024<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=15, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a4339264059, createdName=wzt9715, createdTime=Mon Jul 08 17:18:18 CST 2024, time=2024-07-08, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2215381, encodeId=711222153815e, content=请问大家有没有刊物其他联系方式啊?Technical check已经20天了,中间发了两次邮件给srep@nature.com询问情况没有回复, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=5, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c1e89286195, createdName=ms9000000825188207, createdTime=Wed Jul 17 11:04:00 CST 2024, time=2024-07-17, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2149028, encodeId=0e1221490283b, content=20天了还在技术审查,怎么办, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=78a86574728, createdName=ms9000001459812965, createdTime=Thu Jul 20 16:52:18 CST 2023, time=2023-07-20, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2123237, encodeId=e628212323e60, content=请问Technical check in progress 这个过程需要多少天?谢谢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=84, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1edb5535080, createdName=英雄77, createdTime=Sun Apr 02 08:36:46 CST 2023, time=2023-04-02, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2214210, encodeId=6d832214210af, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向:临床<br>经验分享:Ready for editorial assignment 这个状态1w了,真难顶<a href='/topic/show?id=508e6e03203' target=_blank style='color:#2F92EE;'>#炎症性肠病患者#</a>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=1, topicName=null, topicId=null, topicList=[TopicDto(id=67032, encryptionId=508e6e03203, topicName=炎症性肠病患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9d4c8320348, createdName=ms3000000691298775, createdTime=Wed Jul 10 10:29:55 CST 2024, time=2024-07-10, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=2211101, encodeId=bb8122111016a, content=审稿速度:3.0 | 投稿命中率:75.0<br>偏重的研究方向:转化医学;综合期刊<br>经验分享:2023年度影响因子为4.3分,未来估计在3.5-4.5之间, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=30, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=侠胆医心, createdTime=Sat Jun 22 05:48:52 CST 2024, time=2024-06-22, status=1, ipAttribution=威斯康星), GetPortalCommentsPageByObjectIdResponse(id=2188542, encodeId=ca19218854206, content=偏重的研究方向:炎症性肠病<br>经验分享:接受了,投稿历程发出来给大伙参考一下。<br>Submission history<br>Publishing and rights<br>Submission status Date<br>Submission is in publishing and rights<br>21 Feb 2024<br>Peer review<br>Submission status Date<br>Submission accepted<br>21 Feb 2024<br>Submission under peer review<br>07 Feb 2024<br>Submission passed technical check<br>07 Feb 2024<br>Amendment received<br>07 Feb 2024<br>Revision received<br>31 Jan 2024<br>Submission under peer review<br>24 Jan 2024<br>Submission passed technical check<br>24 Jan 2024<br>Revision received<br>05 Jan 2024<br>Submission under peer review<br>30 Sep 2023<br>Technical check<br>Submission status Date<br>Submission passed technical check<br>30 Sep 2023<br>Amendment received<br>30 Sep 2023<br>Submission is under technical check<br>29 Sep 2023<br>Submission received<br>Submission status Date<br>Submission received<br>29 Sep 2023, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ef635598785, createdName=超超不吵吵, createdTime=Wed Feb 21 18:24:57 CST 2024, time=2024-02-21, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2212907, encodeId=e4f6221290e0d, content=现在是JCR Q1,中科院二区吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=21, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6a638109651, createdName=清清欢, createdTime=Wed Jul 03 08:33:02 CST 2024, time=2024-07-03, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=2206934, encodeId=464822069349a, content=审稿速度:6.0 | 投稿命中率:50.0<br>偏重的研究方向:免疫;肿瘤<br>经验分享:请问大家,有没有人询问审稿进度之后,给重新指派了个编辑的?<br>Editor assigned<br>On 27 May, 2024<br>Editor invited<br>On 28 Mar, 2024<br>Submission checks complete<br>On 28 Mar, 2024<br>First submitted to Scientific Reports<br>On 15 Mar, 2024, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=34, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8a036530258, createdName=ms7000000411552686, createdTime=Mon May 27 20:49:59 CST 2024, time=2024-05-27, status=1, ipAttribution=甘肃省)]
    2024-07-08 wzt9715 来自广东省

    审稿速度:6.0 | 投稿命中率:50.0
    经验分享:2024-7-8:记录最新过程,接近3个月了才送外审,速度真的挺慢了。
    Submission received
    Submission status Date
    Submission received 11 Apr 2024
    Technical check
    Submission status Date
    Submission is under technical check 11 Apr 2024
    Amendment received 16 Apr 2024
    Amendment received 17 Apr 2024
    Submission passed technical check 18 Apr 2024
    Editorial assignment
    Submission status Date
    Ready for editorial assignment 18 Apr 2024
    With editor
    Submission status Date
    Editor assigned 02 Jul 2024
    Peer review
    Submission status Date
    Submission under peer review 08 Jul 2024

    15

    展开15条回复
  3. [GetPortalCommentsPageByObjectIdResponse(id=601248, encodeId=ba9260124873, content=请问询问稿件状态发哪个邮箱啊 scientificreports@nature.com 我问的这个邮箱一直没有回复我, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=83, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201102/9c373b6157ec4a72af667f0eaee06cc2/38088b6d8f154d46874faf3a78361584.jpg, createdBy=9c075117529, createdName=1462b19em97暂无昵称, createdTime=Wed Jun 03 11:34:22 CST 2020, time=2020-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2213965, encodeId=94542213965a9, content=审稿速度:6.0 | 投稿命中率:50.0<br>经验分享:2024-7-8:记录最新过程,接近3个月了才送外审,速度真的挺慢了。<br>Submission received<br>Submission status Date<br>Submission received 11 Apr 2024<br>Technical check<br>Submission status Date<br>Submission is under technical check 11 Apr 2024<br>Amendment received 16 Apr 2024<br>Amendment received 17 Apr 2024<br>Submission passed technical check 18 Apr 2024<br>Editorial assignment<br>Submission status Date<br>Ready for editorial assignment 18 Apr 2024<br>With editor<br>Submission status Date <br>Editor assigned 02 Jul 2024<br>Peer review<br>Submission status Date<br>Submission under peer review 08 Jul 2024<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=15, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a4339264059, createdName=wzt9715, createdTime=Mon Jul 08 17:18:18 CST 2024, time=2024-07-08, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2215381, encodeId=711222153815e, content=请问大家有没有刊物其他联系方式啊?Technical check已经20天了,中间发了两次邮件给srep@nature.com询问情况没有回复, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=5, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c1e89286195, createdName=ms9000000825188207, createdTime=Wed Jul 17 11:04:00 CST 2024, time=2024-07-17, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2149028, encodeId=0e1221490283b, content=20天了还在技术审查,怎么办, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=78a86574728, createdName=ms9000001459812965, createdTime=Thu Jul 20 16:52:18 CST 2023, time=2023-07-20, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2123237, encodeId=e628212323e60, content=请问Technical check in progress 这个过程需要多少天?谢谢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=84, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1edb5535080, createdName=英雄77, createdTime=Sun Apr 02 08:36:46 CST 2023, time=2023-04-02, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2214210, encodeId=6d832214210af, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向:临床<br>经验分享:Ready for editorial assignment 这个状态1w了,真难顶<a href='/topic/show?id=508e6e03203' target=_blank style='color:#2F92EE;'>#炎症性肠病患者#</a>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=1, topicName=null, topicId=null, topicList=[TopicDto(id=67032, encryptionId=508e6e03203, topicName=炎症性肠病患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9d4c8320348, createdName=ms3000000691298775, createdTime=Wed Jul 10 10:29:55 CST 2024, time=2024-07-10, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=2211101, encodeId=bb8122111016a, content=审稿速度:3.0 | 投稿命中率:75.0<br>偏重的研究方向:转化医学;综合期刊<br>经验分享:2023年度影响因子为4.3分,未来估计在3.5-4.5之间, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=30, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=侠胆医心, createdTime=Sat Jun 22 05:48:52 CST 2024, time=2024-06-22, status=1, ipAttribution=威斯康星), GetPortalCommentsPageByObjectIdResponse(id=2188542, encodeId=ca19218854206, content=偏重的研究方向:炎症性肠病<br>经验分享:接受了,投稿历程发出来给大伙参考一下。<br>Submission history<br>Publishing and rights<br>Submission status Date<br>Submission is in publishing and rights<br>21 Feb 2024<br>Peer review<br>Submission status Date<br>Submission accepted<br>21 Feb 2024<br>Submission under peer review<br>07 Feb 2024<br>Submission passed technical check<br>07 Feb 2024<br>Amendment received<br>07 Feb 2024<br>Revision received<br>31 Jan 2024<br>Submission under peer review<br>24 Jan 2024<br>Submission passed technical check<br>24 Jan 2024<br>Revision received<br>05 Jan 2024<br>Submission under peer review<br>30 Sep 2023<br>Technical check<br>Submission status Date<br>Submission passed technical check<br>30 Sep 2023<br>Amendment received<br>30 Sep 2023<br>Submission is under technical check<br>29 Sep 2023<br>Submission received<br>Submission status Date<br>Submission received<br>29 Sep 2023, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ef635598785, createdName=超超不吵吵, createdTime=Wed Feb 21 18:24:57 CST 2024, time=2024-02-21, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2212907, encodeId=e4f6221290e0d, content=现在是JCR Q1,中科院二区吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=21, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6a638109651, createdName=清清欢, createdTime=Wed Jul 03 08:33:02 CST 2024, time=2024-07-03, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=2206934, encodeId=464822069349a, content=审稿速度:6.0 | 投稿命中率:50.0<br>偏重的研究方向:免疫;肿瘤<br>经验分享:请问大家,有没有人询问审稿进度之后,给重新指派了个编辑的?<br>Editor assigned<br>On 27 May, 2024<br>Editor invited<br>On 28 Mar, 2024<br>Submission checks complete<br>On 28 Mar, 2024<br>First submitted to Scientific Reports<br>On 15 Mar, 2024, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=34, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8a036530258, createdName=ms7000000411552686, createdTime=Mon May 27 20:49:59 CST 2024, time=2024-05-27, status=1, ipAttribution=甘肃省)]
    2024-07-17 ms9000000825188207 来自湖北省

    请问大家有没有刊物其他联系方式啊?Technical check已经20天了,中间发了两次邮件给srep@nature.com询问情况没有回复

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=601248, encodeId=ba9260124873, content=请问询问稿件状态发哪个邮箱啊 scientificreports@nature.com 我问的这个邮箱一直没有回复我, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=83, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201102/9c373b6157ec4a72af667f0eaee06cc2/38088b6d8f154d46874faf3a78361584.jpg, createdBy=9c075117529, createdName=1462b19em97暂无昵称, createdTime=Wed Jun 03 11:34:22 CST 2020, time=2020-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2213965, encodeId=94542213965a9, content=审稿速度:6.0 | 投稿命中率:50.0<br>经验分享:2024-7-8:记录最新过程,接近3个月了才送外审,速度真的挺慢了。<br>Submission received<br>Submission status Date<br>Submission received 11 Apr 2024<br>Technical check<br>Submission status Date<br>Submission is under technical check 11 Apr 2024<br>Amendment received 16 Apr 2024<br>Amendment received 17 Apr 2024<br>Submission passed technical check 18 Apr 2024<br>Editorial assignment<br>Submission status Date<br>Ready for editorial assignment 18 Apr 2024<br>With editor<br>Submission status Date <br>Editor assigned 02 Jul 2024<br>Peer review<br>Submission status Date<br>Submission under peer review 08 Jul 2024<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=15, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a4339264059, createdName=wzt9715, createdTime=Mon Jul 08 17:18:18 CST 2024, time=2024-07-08, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2215381, encodeId=711222153815e, content=请问大家有没有刊物其他联系方式啊?Technical check已经20天了,中间发了两次邮件给srep@nature.com询问情况没有回复, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=5, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c1e89286195, createdName=ms9000000825188207, createdTime=Wed Jul 17 11:04:00 CST 2024, time=2024-07-17, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2149028, encodeId=0e1221490283b, content=20天了还在技术审查,怎么办, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=78a86574728, createdName=ms9000001459812965, createdTime=Thu Jul 20 16:52:18 CST 2023, time=2023-07-20, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2123237, encodeId=e628212323e60, content=请问Technical check in progress 这个过程需要多少天?谢谢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=84, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1edb5535080, createdName=英雄77, createdTime=Sun Apr 02 08:36:46 CST 2023, time=2023-04-02, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2214210, encodeId=6d832214210af, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向:临床<br>经验分享:Ready for editorial assignment 这个状态1w了,真难顶<a href='/topic/show?id=508e6e03203' target=_blank style='color:#2F92EE;'>#炎症性肠病患者#</a>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=1, topicName=null, topicId=null, topicList=[TopicDto(id=67032, encryptionId=508e6e03203, topicName=炎症性肠病患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9d4c8320348, createdName=ms3000000691298775, createdTime=Wed Jul 10 10:29:55 CST 2024, time=2024-07-10, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=2211101, encodeId=bb8122111016a, content=审稿速度:3.0 | 投稿命中率:75.0<br>偏重的研究方向:转化医学;综合期刊<br>经验分享:2023年度影响因子为4.3分,未来估计在3.5-4.5之间, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=30, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=侠胆医心, createdTime=Sat Jun 22 05:48:52 CST 2024, time=2024-06-22, status=1, ipAttribution=威斯康星), GetPortalCommentsPageByObjectIdResponse(id=2188542, encodeId=ca19218854206, content=偏重的研究方向:炎症性肠病<br>经验分享:接受了,投稿历程发出来给大伙参考一下。<br>Submission history<br>Publishing and rights<br>Submission status Date<br>Submission is in publishing and rights<br>21 Feb 2024<br>Peer review<br>Submission status Date<br>Submission accepted<br>21 Feb 2024<br>Submission under peer review<br>07 Feb 2024<br>Submission passed technical check<br>07 Feb 2024<br>Amendment received<br>07 Feb 2024<br>Revision received<br>31 Jan 2024<br>Submission under peer review<br>24 Jan 2024<br>Submission passed technical check<br>24 Jan 2024<br>Revision received<br>05 Jan 2024<br>Submission under peer review<br>30 Sep 2023<br>Technical check<br>Submission status Date<br>Submission passed technical check<br>30 Sep 2023<br>Amendment received<br>30 Sep 2023<br>Submission is under technical check<br>29 Sep 2023<br>Submission received<br>Submission status Date<br>Submission received<br>29 Sep 2023, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ef635598785, createdName=超超不吵吵, createdTime=Wed Feb 21 18:24:57 CST 2024, time=2024-02-21, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2212907, encodeId=e4f6221290e0d, content=现在是JCR Q1,中科院二区吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=21, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6a638109651, createdName=清清欢, createdTime=Wed Jul 03 08:33:02 CST 2024, time=2024-07-03, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=2206934, encodeId=464822069349a, content=审稿速度:6.0 | 投稿命中率:50.0<br>偏重的研究方向:免疫;肿瘤<br>经验分享:请问大家,有没有人询问审稿进度之后,给重新指派了个编辑的?<br>Editor assigned<br>On 27 May, 2024<br>Editor invited<br>On 28 Mar, 2024<br>Submission checks complete<br>On 28 Mar, 2024<br>First submitted to Scientific Reports<br>On 15 Mar, 2024, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=34, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8a036530258, createdName=ms7000000411552686, createdTime=Mon May 27 20:49:59 CST 2024, time=2024-05-27, status=1, ipAttribution=甘肃省)]
    2023-07-20 ms9000001459812965 来自陕西省

    20天了还在技术审查,怎么办

    3

    展开3条回复
  5. [GetPortalCommentsPageByObjectIdResponse(id=601248, encodeId=ba9260124873, content=请问询问稿件状态发哪个邮箱啊 scientificreports@nature.com 我问的这个邮箱一直没有回复我, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=83, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201102/9c373b6157ec4a72af667f0eaee06cc2/38088b6d8f154d46874faf3a78361584.jpg, createdBy=9c075117529, createdName=1462b19em97暂无昵称, createdTime=Wed Jun 03 11:34:22 CST 2020, time=2020-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2213965, encodeId=94542213965a9, content=审稿速度:6.0 | 投稿命中率:50.0<br>经验分享:2024-7-8:记录最新过程,接近3个月了才送外审,速度真的挺慢了。<br>Submission received<br>Submission status Date<br>Submission received 11 Apr 2024<br>Technical check<br>Submission status Date<br>Submission is under technical check 11 Apr 2024<br>Amendment received 16 Apr 2024<br>Amendment received 17 Apr 2024<br>Submission passed technical check 18 Apr 2024<br>Editorial assignment<br>Submission status Date<br>Ready for editorial assignment 18 Apr 2024<br>With editor<br>Submission status Date <br>Editor assigned 02 Jul 2024<br>Peer review<br>Submission status Date<br>Submission under peer review 08 Jul 2024<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=15, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a4339264059, createdName=wzt9715, createdTime=Mon Jul 08 17:18:18 CST 2024, time=2024-07-08, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2215381, encodeId=711222153815e, content=请问大家有没有刊物其他联系方式啊?Technical check已经20天了,中间发了两次邮件给srep@nature.com询问情况没有回复, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=5, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c1e89286195, createdName=ms9000000825188207, createdTime=Wed Jul 17 11:04:00 CST 2024, time=2024-07-17, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2149028, encodeId=0e1221490283b, content=20天了还在技术审查,怎么办, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=78a86574728, createdName=ms9000001459812965, createdTime=Thu Jul 20 16:52:18 CST 2023, time=2023-07-20, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2123237, encodeId=e628212323e60, content=请问Technical check in progress 这个过程需要多少天?谢谢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=84, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1edb5535080, createdName=英雄77, createdTime=Sun Apr 02 08:36:46 CST 2023, time=2023-04-02, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2214210, encodeId=6d832214210af, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向:临床<br>经验分享:Ready for editorial assignment 这个状态1w了,真难顶<a href='/topic/show?id=508e6e03203' target=_blank style='color:#2F92EE;'>#炎症性肠病患者#</a>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=1, topicName=null, topicId=null, topicList=[TopicDto(id=67032, encryptionId=508e6e03203, topicName=炎症性肠病患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9d4c8320348, createdName=ms3000000691298775, createdTime=Wed Jul 10 10:29:55 CST 2024, time=2024-07-10, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=2211101, encodeId=bb8122111016a, content=审稿速度:3.0 | 投稿命中率:75.0<br>偏重的研究方向:转化医学;综合期刊<br>经验分享:2023年度影响因子为4.3分,未来估计在3.5-4.5之间, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=30, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=侠胆医心, createdTime=Sat Jun 22 05:48:52 CST 2024, time=2024-06-22, status=1, ipAttribution=威斯康星), GetPortalCommentsPageByObjectIdResponse(id=2188542, encodeId=ca19218854206, content=偏重的研究方向:炎症性肠病<br>经验分享:接受了,投稿历程发出来给大伙参考一下。<br>Submission history<br>Publishing and rights<br>Submission status Date<br>Submission is in publishing and rights<br>21 Feb 2024<br>Peer review<br>Submission status Date<br>Submission accepted<br>21 Feb 2024<br>Submission under peer review<br>07 Feb 2024<br>Submission passed technical check<br>07 Feb 2024<br>Amendment received<br>07 Feb 2024<br>Revision received<br>31 Jan 2024<br>Submission under peer review<br>24 Jan 2024<br>Submission passed technical check<br>24 Jan 2024<br>Revision received<br>05 Jan 2024<br>Submission under peer review<br>30 Sep 2023<br>Technical check<br>Submission status Date<br>Submission passed technical check<br>30 Sep 2023<br>Amendment received<br>30 Sep 2023<br>Submission is under technical check<br>29 Sep 2023<br>Submission received<br>Submission status Date<br>Submission received<br>29 Sep 2023, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ef635598785, createdName=超超不吵吵, createdTime=Wed Feb 21 18:24:57 CST 2024, time=2024-02-21, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2212907, encodeId=e4f6221290e0d, content=现在是JCR Q1,中科院二区吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=21, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6a638109651, createdName=清清欢, createdTime=Wed Jul 03 08:33:02 CST 2024, time=2024-07-03, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=2206934, encodeId=464822069349a, content=审稿速度:6.0 | 投稿命中率:50.0<br>偏重的研究方向:免疫;肿瘤<br>经验分享:请问大家,有没有人询问审稿进度之后,给重新指派了个编辑的?<br>Editor assigned<br>On 27 May, 2024<br>Editor invited<br>On 28 Mar, 2024<br>Submission checks complete<br>On 28 Mar, 2024<br>First submitted to Scientific Reports<br>On 15 Mar, 2024, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=34, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8a036530258, createdName=ms7000000411552686, createdTime=Mon May 27 20:49:59 CST 2024, time=2024-05-27, status=1, ipAttribution=甘肃省)]
    2023-04-02 英雄77 来自吉林省

    请问Technical check in progress 这个过程需要多少天?谢谢

    5

    展开5条回复
  6. [GetPortalCommentsPageByObjectIdResponse(id=601248, encodeId=ba9260124873, content=请问询问稿件状态发哪个邮箱啊 scientificreports@nature.com 我问的这个邮箱一直没有回复我, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=83, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201102/9c373b6157ec4a72af667f0eaee06cc2/38088b6d8f154d46874faf3a78361584.jpg, createdBy=9c075117529, createdName=1462b19em97暂无昵称, createdTime=Wed Jun 03 11:34:22 CST 2020, time=2020-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2213965, encodeId=94542213965a9, content=审稿速度:6.0 | 投稿命中率:50.0<br>经验分享:2024-7-8:记录最新过程,接近3个月了才送外审,速度真的挺慢了。<br>Submission received<br>Submission status Date<br>Submission received 11 Apr 2024<br>Technical check<br>Submission status Date<br>Submission is under technical check 11 Apr 2024<br>Amendment received 16 Apr 2024<br>Amendment received 17 Apr 2024<br>Submission passed technical check 18 Apr 2024<br>Editorial assignment<br>Submission status Date<br>Ready for editorial assignment 18 Apr 2024<br>With editor<br>Submission status Date <br>Editor assigned 02 Jul 2024<br>Peer review<br>Submission status Date<br>Submission under peer review 08 Jul 2024<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=15, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a4339264059, createdName=wzt9715, createdTime=Mon Jul 08 17:18:18 CST 2024, time=2024-07-08, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2215381, encodeId=711222153815e, content=请问大家有没有刊物其他联系方式啊?Technical check已经20天了,中间发了两次邮件给srep@nature.com询问情况没有回复, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=5, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c1e89286195, createdName=ms9000000825188207, createdTime=Wed Jul 17 11:04:00 CST 2024, time=2024-07-17, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2149028, encodeId=0e1221490283b, content=20天了还在技术审查,怎么办, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=78a86574728, createdName=ms9000001459812965, createdTime=Thu Jul 20 16:52:18 CST 2023, time=2023-07-20, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2123237, encodeId=e628212323e60, content=请问Technical check in progress 这个过程需要多少天?谢谢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=84, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1edb5535080, createdName=英雄77, createdTime=Sun Apr 02 08:36:46 CST 2023, time=2023-04-02, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2214210, encodeId=6d832214210af, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向:临床<br>经验分享:Ready for editorial assignment 这个状态1w了,真难顶<a href='/topic/show?id=508e6e03203' target=_blank style='color:#2F92EE;'>#炎症性肠病患者#</a>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=1, topicName=null, topicId=null, topicList=[TopicDto(id=67032, encryptionId=508e6e03203, topicName=炎症性肠病患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9d4c8320348, createdName=ms3000000691298775, createdTime=Wed Jul 10 10:29:55 CST 2024, time=2024-07-10, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=2211101, encodeId=bb8122111016a, content=审稿速度:3.0 | 投稿命中率:75.0<br>偏重的研究方向:转化医学;综合期刊<br>经验分享:2023年度影响因子为4.3分,未来估计在3.5-4.5之间, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=30, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=侠胆医心, createdTime=Sat Jun 22 05:48:52 CST 2024, time=2024-06-22, status=1, ipAttribution=威斯康星), GetPortalCommentsPageByObjectIdResponse(id=2188542, encodeId=ca19218854206, content=偏重的研究方向:炎症性肠病<br>经验分享:接受了,投稿历程发出来给大伙参考一下。<br>Submission history<br>Publishing and rights<br>Submission status Date<br>Submission is in publishing and rights<br>21 Feb 2024<br>Peer review<br>Submission status Date<br>Submission accepted<br>21 Feb 2024<br>Submission under peer review<br>07 Feb 2024<br>Submission passed technical check<br>07 Feb 2024<br>Amendment received<br>07 Feb 2024<br>Revision received<br>31 Jan 2024<br>Submission under peer review<br>24 Jan 2024<br>Submission passed technical check<br>24 Jan 2024<br>Revision received<br>05 Jan 2024<br>Submission under peer review<br>30 Sep 2023<br>Technical check<br>Submission status Date<br>Submission passed technical check<br>30 Sep 2023<br>Amendment received<br>30 Sep 2023<br>Submission is under technical check<br>29 Sep 2023<br>Submission received<br>Submission status Date<br>Submission received<br>29 Sep 2023, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ef635598785, createdName=超超不吵吵, createdTime=Wed Feb 21 18:24:57 CST 2024, time=2024-02-21, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2212907, encodeId=e4f6221290e0d, content=现在是JCR Q1,中科院二区吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=21, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6a638109651, createdName=清清欢, createdTime=Wed Jul 03 08:33:02 CST 2024, time=2024-07-03, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=2206934, encodeId=464822069349a, content=审稿速度:6.0 | 投稿命中率:50.0<br>偏重的研究方向:免疫;肿瘤<br>经验分享:请问大家,有没有人询问审稿进度之后,给重新指派了个编辑的?<br>Editor assigned<br>On 27 May, 2024<br>Editor invited<br>On 28 Mar, 2024<br>Submission checks complete<br>On 28 Mar, 2024<br>First submitted to Scientific Reports<br>On 15 Mar, 2024, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=34, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8a036530258, createdName=ms7000000411552686, createdTime=Mon May 27 20:49:59 CST 2024, time=2024-05-27, status=1, ipAttribution=甘肃省)]
    2024-07-10 ms3000000691298775 来自江西省

    审稿速度:3.0 | 投稿命中率:50.0
    偏重的研究方向:临床
    经验分享:Ready for editorial assignment 这个状态1w了,真难顶#炎症性肠病患者#

    1

    展开1条回复
  7. [GetPortalCommentsPageByObjectIdResponse(id=601248, encodeId=ba9260124873, content=请问询问稿件状态发哪个邮箱啊 scientificreports@nature.com 我问的这个邮箱一直没有回复我, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=83, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201102/9c373b6157ec4a72af667f0eaee06cc2/38088b6d8f154d46874faf3a78361584.jpg, createdBy=9c075117529, createdName=1462b19em97暂无昵称, createdTime=Wed Jun 03 11:34:22 CST 2020, time=2020-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2213965, encodeId=94542213965a9, content=审稿速度:6.0 | 投稿命中率:50.0<br>经验分享:2024-7-8:记录最新过程,接近3个月了才送外审,速度真的挺慢了。<br>Submission received<br>Submission status Date<br>Submission received 11 Apr 2024<br>Technical check<br>Submission status Date<br>Submission is under technical check 11 Apr 2024<br>Amendment received 16 Apr 2024<br>Amendment received 17 Apr 2024<br>Submission passed technical check 18 Apr 2024<br>Editorial assignment<br>Submission status Date<br>Ready for editorial assignment 18 Apr 2024<br>With editor<br>Submission status Date <br>Editor assigned 02 Jul 2024<br>Peer review<br>Submission status Date<br>Submission under peer review 08 Jul 2024<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=15, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a4339264059, createdName=wzt9715, createdTime=Mon Jul 08 17:18:18 CST 2024, time=2024-07-08, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2215381, encodeId=711222153815e, content=请问大家有没有刊物其他联系方式啊?Technical check已经20天了,中间发了两次邮件给srep@nature.com询问情况没有回复, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=5, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c1e89286195, createdName=ms9000000825188207, createdTime=Wed Jul 17 11:04:00 CST 2024, time=2024-07-17, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2149028, encodeId=0e1221490283b, content=20天了还在技术审查,怎么办, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=78a86574728, createdName=ms9000001459812965, createdTime=Thu Jul 20 16:52:18 CST 2023, time=2023-07-20, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2123237, encodeId=e628212323e60, content=请问Technical check in progress 这个过程需要多少天?谢谢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=84, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1edb5535080, createdName=英雄77, createdTime=Sun Apr 02 08:36:46 CST 2023, time=2023-04-02, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2214210, encodeId=6d832214210af, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向:临床<br>经验分享:Ready for editorial assignment 这个状态1w了,真难顶<a href='/topic/show?id=508e6e03203' target=_blank style='color:#2F92EE;'>#炎症性肠病患者#</a>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=1, topicName=null, topicId=null, topicList=[TopicDto(id=67032, encryptionId=508e6e03203, topicName=炎症性肠病患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9d4c8320348, createdName=ms3000000691298775, createdTime=Wed Jul 10 10:29:55 CST 2024, time=2024-07-10, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=2211101, encodeId=bb8122111016a, content=审稿速度:3.0 | 投稿命中率:75.0<br>偏重的研究方向:转化医学;综合期刊<br>经验分享:2023年度影响因子为4.3分,未来估计在3.5-4.5之间, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=30, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=侠胆医心, createdTime=Sat Jun 22 05:48:52 CST 2024, time=2024-06-22, status=1, ipAttribution=威斯康星), GetPortalCommentsPageByObjectIdResponse(id=2188542, encodeId=ca19218854206, content=偏重的研究方向:炎症性肠病<br>经验分享:接受了,投稿历程发出来给大伙参考一下。<br>Submission history<br>Publishing and rights<br>Submission status Date<br>Submission is in publishing and rights<br>21 Feb 2024<br>Peer review<br>Submission status Date<br>Submission accepted<br>21 Feb 2024<br>Submission under peer review<br>07 Feb 2024<br>Submission passed technical check<br>07 Feb 2024<br>Amendment received<br>07 Feb 2024<br>Revision received<br>31 Jan 2024<br>Submission under peer review<br>24 Jan 2024<br>Submission passed technical check<br>24 Jan 2024<br>Revision received<br>05 Jan 2024<br>Submission under peer review<br>30 Sep 2023<br>Technical check<br>Submission status Date<br>Submission passed technical check<br>30 Sep 2023<br>Amendment received<br>30 Sep 2023<br>Submission is under technical check<br>29 Sep 2023<br>Submission received<br>Submission status Date<br>Submission received<br>29 Sep 2023, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ef635598785, createdName=超超不吵吵, createdTime=Wed Feb 21 18:24:57 CST 2024, time=2024-02-21, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2212907, encodeId=e4f6221290e0d, content=现在是JCR Q1,中科院二区吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=21, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6a638109651, createdName=清清欢, createdTime=Wed Jul 03 08:33:02 CST 2024, time=2024-07-03, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=2206934, encodeId=464822069349a, content=审稿速度:6.0 | 投稿命中率:50.0<br>偏重的研究方向:免疫;肿瘤<br>经验分享:请问大家,有没有人询问审稿进度之后,给重新指派了个编辑的?<br>Editor assigned<br>On 27 May, 2024<br>Editor invited<br>On 28 Mar, 2024<br>Submission checks complete<br>On 28 Mar, 2024<br>First submitted to Scientific Reports<br>On 15 Mar, 2024, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=34, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8a036530258, createdName=ms7000000411552686, createdTime=Mon May 27 20:49:59 CST 2024, time=2024-05-27, status=1, ipAttribution=甘肃省)]
    2024-06-22 侠胆医心 来自威斯康星

    审稿速度:3.0 | 投稿命中率:75.0
    偏重的研究方向:转化医学;综合期刊
    经验分享:2023年度影响因子为4.3分,未来估计在3.5-4.5之间

    2

    展开2条回复
  8. [GetPortalCommentsPageByObjectIdResponse(id=601248, encodeId=ba9260124873, content=请问询问稿件状态发哪个邮箱啊 scientificreports@nature.com 我问的这个邮箱一直没有回复我, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=83, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201102/9c373b6157ec4a72af667f0eaee06cc2/38088b6d8f154d46874faf3a78361584.jpg, createdBy=9c075117529, createdName=1462b19em97暂无昵称, createdTime=Wed Jun 03 11:34:22 CST 2020, time=2020-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2213965, encodeId=94542213965a9, content=审稿速度:6.0 | 投稿命中率:50.0<br>经验分享:2024-7-8:记录最新过程,接近3个月了才送外审,速度真的挺慢了。<br>Submission received<br>Submission status Date<br>Submission received 11 Apr 2024<br>Technical check<br>Submission status Date<br>Submission is under technical check 11 Apr 2024<br>Amendment received 16 Apr 2024<br>Amendment received 17 Apr 2024<br>Submission passed technical check 18 Apr 2024<br>Editorial assignment<br>Submission status Date<br>Ready for editorial assignment 18 Apr 2024<br>With editor<br>Submission status Date <br>Editor assigned 02 Jul 2024<br>Peer review<br>Submission status Date<br>Submission under peer review 08 Jul 2024<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=15, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a4339264059, createdName=wzt9715, createdTime=Mon Jul 08 17:18:18 CST 2024, time=2024-07-08, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2215381, encodeId=711222153815e, content=请问大家有没有刊物其他联系方式啊?Technical check已经20天了,中间发了两次邮件给srep@nature.com询问情况没有回复, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=5, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c1e89286195, createdName=ms9000000825188207, createdTime=Wed Jul 17 11:04:00 CST 2024, time=2024-07-17, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2149028, encodeId=0e1221490283b, content=20天了还在技术审查,怎么办, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=78a86574728, createdName=ms9000001459812965, createdTime=Thu Jul 20 16:52:18 CST 2023, time=2023-07-20, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2123237, encodeId=e628212323e60, content=请问Technical check in progress 这个过程需要多少天?谢谢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=84, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1edb5535080, createdName=英雄77, createdTime=Sun Apr 02 08:36:46 CST 2023, time=2023-04-02, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2214210, encodeId=6d832214210af, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向:临床<br>经验分享:Ready for editorial assignment 这个状态1w了,真难顶<a href='/topic/show?id=508e6e03203' target=_blank style='color:#2F92EE;'>#炎症性肠病患者#</a>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=1, topicName=null, topicId=null, topicList=[TopicDto(id=67032, encryptionId=508e6e03203, topicName=炎症性肠病患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9d4c8320348, createdName=ms3000000691298775, createdTime=Wed Jul 10 10:29:55 CST 2024, time=2024-07-10, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=2211101, encodeId=bb8122111016a, content=审稿速度:3.0 | 投稿命中率:75.0<br>偏重的研究方向:转化医学;综合期刊<br>经验分享:2023年度影响因子为4.3分,未来估计在3.5-4.5之间, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=30, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=侠胆医心, createdTime=Sat Jun 22 05:48:52 CST 2024, time=2024-06-22, status=1, ipAttribution=威斯康星), GetPortalCommentsPageByObjectIdResponse(id=2188542, encodeId=ca19218854206, content=偏重的研究方向:炎症性肠病<br>经验分享:接受了,投稿历程发出来给大伙参考一下。<br>Submission history<br>Publishing and rights<br>Submission status Date<br>Submission is in publishing and rights<br>21 Feb 2024<br>Peer review<br>Submission status Date<br>Submission accepted<br>21 Feb 2024<br>Submission under peer review<br>07 Feb 2024<br>Submission passed technical check<br>07 Feb 2024<br>Amendment received<br>07 Feb 2024<br>Revision received<br>31 Jan 2024<br>Submission under peer review<br>24 Jan 2024<br>Submission passed technical check<br>24 Jan 2024<br>Revision received<br>05 Jan 2024<br>Submission under peer review<br>30 Sep 2023<br>Technical check<br>Submission status Date<br>Submission passed technical check<br>30 Sep 2023<br>Amendment received<br>30 Sep 2023<br>Submission is under technical check<br>29 Sep 2023<br>Submission received<br>Submission status Date<br>Submission received<br>29 Sep 2023, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ef635598785, createdName=超超不吵吵, createdTime=Wed Feb 21 18:24:57 CST 2024, time=2024-02-21, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2212907, encodeId=e4f6221290e0d, content=现在是JCR Q1,中科院二区吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=21, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6a638109651, createdName=清清欢, createdTime=Wed Jul 03 08:33:02 CST 2024, time=2024-07-03, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=2206934, encodeId=464822069349a, content=审稿速度:6.0 | 投稿命中率:50.0<br>偏重的研究方向:免疫;肿瘤<br>经验分享:请问大家,有没有人询问审稿进度之后,给重新指派了个编辑的?<br>Editor assigned<br>On 27 May, 2024<br>Editor invited<br>On 28 Mar, 2024<br>Submission checks complete<br>On 28 Mar, 2024<br>First submitted to Scientific Reports<br>On 15 Mar, 2024, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=34, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8a036530258, createdName=ms7000000411552686, createdTime=Mon May 27 20:49:59 CST 2024, time=2024-05-27, status=1, ipAttribution=甘肃省)]
    2024-02-21 超超不吵吵 来自湖南省

    偏重的研究方向:炎症性肠病
    经验分享:接受了,投稿历程发出来给大伙参考一下。
    Submission history
    Publishing and rights
    Submission status Date
    Submission is in publishing and rights
    21 Feb 2024
    Peer review
    Submission status Date
    Submission accepted
    21 Feb 2024
    Submission under peer review
    07 Feb 2024
    Submission passed technical check
    07 Feb 2024
    Amendment received
    07 Feb 2024
    Revision received
    31 Jan 2024
    Submission under peer review
    24 Jan 2024
    Submission passed technical check
    24 Jan 2024
    Revision received
    05 Jan 2024
    Submission under peer review
    30 Sep 2023
    Technical check
    Submission status Date
    Submission passed technical check
    30 Sep 2023
    Amendment received
    30 Sep 2023
    Submission is under technical check
    29 Sep 2023
    Submission received
    Submission status Date
    Submission received
    29 Sep 2023

    5

    展开5条回复
  9. [GetPortalCommentsPageByObjectIdResponse(id=601248, encodeId=ba9260124873, content=请问询问稿件状态发哪个邮箱啊 scientificreports@nature.com 我问的这个邮箱一直没有回复我, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=83, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201102/9c373b6157ec4a72af667f0eaee06cc2/38088b6d8f154d46874faf3a78361584.jpg, createdBy=9c075117529, createdName=1462b19em97暂无昵称, createdTime=Wed Jun 03 11:34:22 CST 2020, time=2020-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2213965, encodeId=94542213965a9, content=审稿速度:6.0 | 投稿命中率:50.0<br>经验分享:2024-7-8:记录最新过程,接近3个月了才送外审,速度真的挺慢了。<br>Submission received<br>Submission status Date<br>Submission received 11 Apr 2024<br>Technical check<br>Submission status Date<br>Submission is under technical check 11 Apr 2024<br>Amendment received 16 Apr 2024<br>Amendment received 17 Apr 2024<br>Submission passed technical check 18 Apr 2024<br>Editorial assignment<br>Submission status Date<br>Ready for editorial assignment 18 Apr 2024<br>With editor<br>Submission status Date <br>Editor assigned 02 Jul 2024<br>Peer review<br>Submission status Date<br>Submission under peer review 08 Jul 2024<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=15, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a4339264059, createdName=wzt9715, createdTime=Mon Jul 08 17:18:18 CST 2024, time=2024-07-08, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2215381, encodeId=711222153815e, content=请问大家有没有刊物其他联系方式啊?Technical check已经20天了,中间发了两次邮件给srep@nature.com询问情况没有回复, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=5, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c1e89286195, createdName=ms9000000825188207, createdTime=Wed Jul 17 11:04:00 CST 2024, time=2024-07-17, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2149028, encodeId=0e1221490283b, content=20天了还在技术审查,怎么办, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=78a86574728, createdName=ms9000001459812965, createdTime=Thu Jul 20 16:52:18 CST 2023, time=2023-07-20, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2123237, encodeId=e628212323e60, content=请问Technical check in progress 这个过程需要多少天?谢谢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=84, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1edb5535080, createdName=英雄77, createdTime=Sun Apr 02 08:36:46 CST 2023, time=2023-04-02, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2214210, encodeId=6d832214210af, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向:临床<br>经验分享:Ready for editorial assignment 这个状态1w了,真难顶<a href='/topic/show?id=508e6e03203' target=_blank style='color:#2F92EE;'>#炎症性肠病患者#</a>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=1, topicName=null, topicId=null, topicList=[TopicDto(id=67032, encryptionId=508e6e03203, topicName=炎症性肠病患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9d4c8320348, createdName=ms3000000691298775, createdTime=Wed Jul 10 10:29:55 CST 2024, time=2024-07-10, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=2211101, encodeId=bb8122111016a, content=审稿速度:3.0 | 投稿命中率:75.0<br>偏重的研究方向:转化医学;综合期刊<br>经验分享:2023年度影响因子为4.3分,未来估计在3.5-4.5之间, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=30, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=侠胆医心, createdTime=Sat Jun 22 05:48:52 CST 2024, time=2024-06-22, status=1, ipAttribution=威斯康星), GetPortalCommentsPageByObjectIdResponse(id=2188542, encodeId=ca19218854206, content=偏重的研究方向:炎症性肠病<br>经验分享:接受了,投稿历程发出来给大伙参考一下。<br>Submission history<br>Publishing and rights<br>Submission status Date<br>Submission is in publishing and rights<br>21 Feb 2024<br>Peer review<br>Submission status Date<br>Submission accepted<br>21 Feb 2024<br>Submission under peer review<br>07 Feb 2024<br>Submission passed technical check<br>07 Feb 2024<br>Amendment received<br>07 Feb 2024<br>Revision received<br>31 Jan 2024<br>Submission under peer review<br>24 Jan 2024<br>Submission passed technical check<br>24 Jan 2024<br>Revision received<br>05 Jan 2024<br>Submission under peer review<br>30 Sep 2023<br>Technical check<br>Submission status Date<br>Submission passed technical check<br>30 Sep 2023<br>Amendment received<br>30 Sep 2023<br>Submission is under technical check<br>29 Sep 2023<br>Submission received<br>Submission status Date<br>Submission received<br>29 Sep 2023, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ef635598785, createdName=超超不吵吵, createdTime=Wed Feb 21 18:24:57 CST 2024, time=2024-02-21, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2212907, encodeId=e4f6221290e0d, content=现在是JCR Q1,中科院二区吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=21, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6a638109651, createdName=清清欢, createdTime=Wed Jul 03 08:33:02 CST 2024, time=2024-07-03, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=2206934, encodeId=464822069349a, content=审稿速度:6.0 | 投稿命中率:50.0<br>偏重的研究方向:免疫;肿瘤<br>经验分享:请问大家,有没有人询问审稿进度之后,给重新指派了个编辑的?<br>Editor assigned<br>On 27 May, 2024<br>Editor invited<br>On 28 Mar, 2024<br>Submission checks complete<br>On 28 Mar, 2024<br>First submitted to Scientific Reports<br>On 15 Mar, 2024, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=34, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8a036530258, createdName=ms7000000411552686, createdTime=Mon May 27 20:49:59 CST 2024, time=2024-05-27, status=1, ipAttribution=甘肃省)]
    2024-07-03 清清欢 来自江西省

    现在是JCR Q1,中科院二区吗?

    2

    展开2条回复
  10. [GetPortalCommentsPageByObjectIdResponse(id=601248, encodeId=ba9260124873, content=请问询问稿件状态发哪个邮箱啊 scientificreports@nature.com 我问的这个邮箱一直没有回复我, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=83, replyNumber=6, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201102/9c373b6157ec4a72af667f0eaee06cc2/38088b6d8f154d46874faf3a78361584.jpg, createdBy=9c075117529, createdName=1462b19em97暂无昵称, createdTime=Wed Jun 03 11:34:22 CST 2020, time=2020-06-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2213965, encodeId=94542213965a9, content=审稿速度:6.0 | 投稿命中率:50.0<br>经验分享:2024-7-8:记录最新过程,接近3个月了才送外审,速度真的挺慢了。<br>Submission received<br>Submission status Date<br>Submission received 11 Apr 2024<br>Technical check<br>Submission status Date<br>Submission is under technical check 11 Apr 2024<br>Amendment received 16 Apr 2024<br>Amendment received 17 Apr 2024<br>Submission passed technical check 18 Apr 2024<br>Editorial assignment<br>Submission status Date<br>Ready for editorial assignment 18 Apr 2024<br>With editor<br>Submission status Date <br>Editor assigned 02 Jul 2024<br>Peer review<br>Submission status Date<br>Submission under peer review 08 Jul 2024<br>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=38, replyNumber=15, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a4339264059, createdName=wzt9715, createdTime=Mon Jul 08 17:18:18 CST 2024, time=2024-07-08, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2215381, encodeId=711222153815e, content=请问大家有没有刊物其他联系方式啊?Technical check已经20天了,中间发了两次邮件给srep@nature.com询问情况没有回复, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=5, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c1e89286195, createdName=ms9000000825188207, createdTime=Wed Jul 17 11:04:00 CST 2024, time=2024-07-17, status=1, ipAttribution=湖北省), GetPortalCommentsPageByObjectIdResponse(id=2149028, encodeId=0e1221490283b, content=20天了还在技术审查,怎么办, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=57, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=78a86574728, createdName=ms9000001459812965, createdTime=Thu Jul 20 16:52:18 CST 2023, time=2023-07-20, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2123237, encodeId=e628212323e60, content=请问Technical check in progress 这个过程需要多少天?谢谢, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=84, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1edb5535080, createdName=英雄77, createdTime=Sun Apr 02 08:36:46 CST 2023, time=2023-04-02, status=1, ipAttribution=吉林省), GetPortalCommentsPageByObjectIdResponse(id=2214210, encodeId=6d832214210af, content=审稿速度:3.0 | 投稿命中率:50.0<br>偏重的研究方向:临床<br>经验分享:Ready for editorial assignment 这个状态1w了,真难顶<a href='/topic/show?id=508e6e03203' target=_blank style='color:#2F92EE;'>#炎症性肠病患者#</a>, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=1, topicName=null, topicId=null, topicList=[TopicDto(id=67032, encryptionId=508e6e03203, topicName=炎症性肠病患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9d4c8320348, createdName=ms3000000691298775, createdTime=Wed Jul 10 10:29:55 CST 2024, time=2024-07-10, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=2211101, encodeId=bb8122111016a, content=审稿速度:3.0 | 投稿命中率:75.0<br>偏重的研究方向:转化医学;综合期刊<br>经验分享:2023年度影响因子为4.3分,未来估计在3.5-4.5之间, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=30, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=侠胆医心, createdTime=Sat Jun 22 05:48:52 CST 2024, time=2024-06-22, status=1, ipAttribution=威斯康星), GetPortalCommentsPageByObjectIdResponse(id=2188542, encodeId=ca19218854206, content=偏重的研究方向:炎症性肠病<br>经验分享:接受了,投稿历程发出来给大伙参考一下。<br>Submission history<br>Publishing and rights<br>Submission status Date<br>Submission is in publishing and rights<br>21 Feb 2024<br>Peer review<br>Submission status Date<br>Submission accepted<br>21 Feb 2024<br>Submission under peer review<br>07 Feb 2024<br>Submission passed technical check<br>07 Feb 2024<br>Amendment received<br>07 Feb 2024<br>Revision received<br>31 Jan 2024<br>Submission under peer review<br>24 Jan 2024<br>Submission passed technical check<br>24 Jan 2024<br>Revision received<br>05 Jan 2024<br>Submission under peer review<br>30 Sep 2023<br>Technical check<br>Submission status Date<br>Submission passed technical check<br>30 Sep 2023<br>Amendment received<br>30 Sep 2023<br>Submission is under technical check<br>29 Sep 2023<br>Submission received<br>Submission status Date<br>Submission received<br>29 Sep 2023, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=44, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ef635598785, createdName=超超不吵吵, createdTime=Wed Feb 21 18:24:57 CST 2024, time=2024-02-21, status=1, ipAttribution=湖南省), GetPortalCommentsPageByObjectIdResponse(id=2212907, encodeId=e4f6221290e0d, content=现在是JCR Q1,中科院二区吗?, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=21, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6a638109651, createdName=清清欢, createdTime=Wed Jul 03 08:33:02 CST 2024, time=2024-07-03, status=1, ipAttribution=江西省), GetPortalCommentsPageByObjectIdResponse(id=2206934, encodeId=464822069349a, content=审稿速度:6.0 | 投稿命中率:50.0<br>偏重的研究方向:免疫;肿瘤<br>经验分享:请问大家,有没有人询问审稿进度之后,给重新指派了个编辑的?<br>Editor assigned<br>On 27 May, 2024<br>Editor invited<br>On 28 Mar, 2024<br>Submission checks complete<br>On 28 Mar, 2024<br>First submitted to Scientific Reports<br>On 15 Mar, 2024, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=34, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8a036530258, createdName=ms7000000411552686, createdTime=Mon May 27 20:49:59 CST 2024, time=2024-05-27, status=1, ipAttribution=甘肃省)]
    2024-05-27 ms7000000411552686 来自甘肃省

    审稿速度:6.0 | 投稿命中率:50.0
    偏重的研究方向:免疫;肿瘤
    经验分享:请问大家,有没有人询问审稿进度之后,给重新指派了个编辑的?
    Editor assigned
    On 27 May, 2024
    Editor invited
    On 28 Mar, 2024
    Submission checks complete
    On 28 Mar, 2024
    First submitted to Scientific Reports
    On 15 Mar, 2024

    5

    展开5条回复
共500条页码: 1/50页10条/页
分享您的投稿经验,提升MI经验值,获取更多积分